UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 85 filers reported holding UROGEN PHARMA LTD in Q2 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,559,819 | +24.7% | 92,957 | +11.4% | 0.00% | – |
Q1 2024 | $1,251,285 | 0.0% | 83,419 | 0.0% | 0.00% | – |
Q4 2023 | $1,251,285 | +40.4% | 83,419 | +31.1% | 0.00% | – |
Q3 2023 | $891,512 | +40.1% | 63,634 | +3.5% | 0.00% | – |
Q2 2023 | $636,132 | -25.5% | 61,462 | -35.1% | 0.00% | – |
Q1 2022 | $854,000 | -5.7% | 94,660 | +1.0% | 0.00% | – |
Q4 2021 | $906,000 | -45.9% | 93,752 | -6.5% | 0.00% | -100.0% |
Q3 2021 | $1,674,000 | +13.5% | 100,316 | +3.8% | 0.00% | – |
Q2 2021 | $1,475,000 | -26.2% | 96,600 | -5.9% | 0.00% | -100.0% |
Q1 2021 | $2,000,000 | -43.9% | 102,654 | -48.1% | 0.00% | 0.0% |
Q4 2020 | $3,562,000 | -23.1% | 197,690 | -17.7% | 0.00% | -50.0% |
Q3 2020 | $4,635,000 | -47.4% | 240,248 | -28.7% | 0.00% | -50.0% |
Q2 2020 | $8,807,000 | +82.3% | 337,149 | +24.5% | 0.00% | +100.0% |
Q1 2020 | $4,831,000 | +346.1% | 270,833 | +496.0% | 0.00% | – |
Q3 2019 | $1,083,000 | -29.6% | 45,444 | +6.1% | 0.00% | -100.0% |
Q2 2019 | $1,539,000 | – | 42,826 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |